CSAR 2014: A Benchmark Exercise Using Unpublished Data from Pharma

被引:79
作者
Carlson, Heather A. [1 ]
Smith, Richard D. [1 ]
Damm-Ganamet, Kelly L. [1 ]
Stuckey, Jeanne A. [2 ]
Ahmed, Aqeel [1 ]
Convery, Maire A. [3 ]
Somers, Donald O. [3 ]
Kranz, Michael [3 ]
Elkins, Patricia A. [4 ]
Cui, Guanglei [4 ]
Peishoff, Catherine E. [4 ]
Lambert, Millard H. [4 ]
Dunbar, James B., Jr. [1 ]
机构
[1] Univ Michigan, Coll Pharm, Dept Med Chem, 428 Church St, Ann Arbor, MI 48109 USA
[2] Univ Michigan, Struct Biol Ctr, Life Sci Inst 3358E, 210 Washtenaw Ave, Ann Arbor, MI 48109 USA
[3] GlaxoSmithKline Res & Dev Ltd, Med Res Ctr, Computat & Struct Sci, Gunnels Wood Rd, Stevenage SG1 2NY, Herts, England
[4] GlaxoSmithKline Res & Dev Ltd, Computat & Struct Sci, 1250 South Collegeville Rd, Collegeville, PA 19426 USA
关键词
PROTEIN-LIGAND DOCKING; FACTOR XA INHIBITORS; EMPIRICAL SCORING FUNCTIONS; PROPERTY-BASED DESIGN; SOLVATION FREE-ENERGIES; BINDING-AFFINITY; ACCURATE DOCKING; PREDICTION; PYRROLIDIN-2-ONES; VALIDATION;
D O I
10.1021/acs.jcim.5b00523
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The 2014 CSAR Benchmark Exercise was the last community-wide exercise that was conducted by the group at the University of Michigan, Ann Arbor. For this event, GlaxoSmithKline (GSK) donated unpublished crystal structures and affinity data from in-house projects. Three targets were used: tRNA (m1G37) methyltransferase (TrmD), Spleen Tyrosine Kinase (SYK), and Factor Xa (FXa). A particularly strong feature of the GSK data is its large size, which lends greater statistical significance to comparisons between different methods. In Phase 1 of the CSAR 2014 Exercise, participants were given several protein-ligand complexes and asked to identify the one near-native pose from among 200 decoys provided by CSAR Though decoys were requested by the community, we found that they complicated our analysis. We could not discern whether poor predictions were failures of the chosen method or an incompatibility between the participant's method and the setup protocol we used. This problem is inherent to decoys, and we strongly advise against their use. In Phase 2, participants had to dock and rank/score a set of small molecules given only the SMILES strings of the ligands and a protein structure with a different ligand bound. Overall, docking was a success for most participants, much better in Phase 2 than in Phase 1. However, scoring was a greater challenge. No particular approach to docking and scoring had an edge, and successful methods included empirical, knowledge-based, machine-learning, shape-fitting, and even those with solvation and entropy terms. Several groups were successful in ranking TrmD and/or SYK, but ranking FXa ligands was intractable for all participants. Methods that were able to dock well across all submitted systems include MDock,(1) Glide-XP,(2) PLANTS,(3) Wilma,(4) Gold,(5) SMINA,(6) Glide-XP2/PELE,(7) FlexX,(8) and MedusaDock.(9) In fact, the submission based on Glide-XP2/PELE7 cross-docked all ligands to many crystal structures, and it was particularly impressive to see success across an ensemble of protein structures for multiple targets. For scoring/ranking, submissions that showed statistically significant achievement include MDockl using ITScore(1,10) with a flexible-ligand term,(11) SMINA(6) using Autodock-Vina,(12,13) FlexX using HYDE,14 and Glide-XP2 using XP DockScore2 with and without ROCS15 shape similarity.16 Of course, these results are for only three protein targets, and many more systems need to be investigated to truly identify which approaches are more successful than others. Furthermore, our exercise is not a competition.
引用
收藏
页码:1063 / 1077
页数:15
相关论文
共 107 条
[1]   Antithrombotic potential of GW813893: A novel, orally active, active-site directed factor Xa inhibitor [J].
Abboud, Melanie A. ;
Needle, Saul J. ;
Burns-Kurtis, Cynthia L. ;
Valocik, Richard E. ;
Koster, Paul E. ;
Amour, Augustin J. ;
Chan, Chuen ;
Brown, David ;
Chaudry, Laiq ;
Zhou, Ping ;
Patikis, Angela ;
Patel, Champa ;
Pateman, Anthony J. ;
Young, Rob J. ;
Watson, Nigel S. ;
Toomey, John R. .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2008, 52 (01) :66-71
[2]   Role of the active-site solvent in the thermodynamics of factor Xa ligand binding [J].
Abel, Robert ;
Young, Tom ;
Farid, Ramy ;
Berne, Bruce J. ;
Friesner, Richard A. .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2008, 130 (09) :2817-2831
[3]   Oral Apixaban for the Treatment of Acute Venous Thromboembolism [J].
Agnelli, Giancarlo ;
Buller, Harry R. ;
Cohen, Alexander ;
Curto, Madelyn ;
Gallus, Alexander S. ;
Johnson, Margot ;
Masiukiewicz, Urszula ;
Pak, Raphael ;
Thompson, John ;
Raskob, Gary E. ;
Weitz, Jeffrey I. .
NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (09) :799-808
[4]   Development and application of site mapping methods for the design of glycosaminoglycans [J].
Agostino, Mark ;
Gandhi, Neha S. ;
Mancera, Ricardo L. .
GLYCOBIOLOGY, 2014, 24 (09) :840-851
[5]   DOCK 6: Impact of New Features and Current Docking Performance [J].
Allen, William J. ;
Balius, Trent E. ;
Mukherjee, Sudipto ;
Brozell, Scott R. ;
Moustakas, Demetri T. ;
Lang, P. Therese ;
Case, David A. ;
Kuntz, Irwin D. ;
Rizzo, Robert C. .
JOURNAL OF COMPUTATIONAL CHEMISTRY, 2015, 36 (15) :1132-1156
[6]  
[Anonymous], 2013, MOE2013 08
[7]  
[Anonymous], 2011, MOE2011 10
[8]  
[Anonymous], 2015, ROCS V 3 2 1
[9]  
[Anonymous], JMP PRO 10
[10]  
[Anonymous], 2016, SZYBKI 1 8 0 2